Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Polyclonally Activated, Intentionally Mis-Matched, Allogeneic Th1 Memory Cells (AlloStimTM) in Patients With Relapsed or Refractory Hematological Malignancy Without Prior Conditioning

NCT00861965 is registered in ClinicalTrials.gov with Mirror Biologics, Inc. as lead sponsor.

NCT NCT00861965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00861965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Polyclonally Activated, Intentionally Mis-Matched, Allogeneic Th1 Memory Cells (AlloStimTM) in Patients With Relapsed or Refractory Hematological Malignancy Without Prior Conditioning
Lead sponsor
Mirror Biologics, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
January 31, 2010
Completion date
April 30, 2011
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or refractory leukemia, lymphoma, multiple myeloma